Publication
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Prostate Neoplasmcivic_curation1.00
- drugAbirateronecivic_curation1.00
- drugEnzalutamidecivic_curation1.00
- geneARcivic_curation1.00
- variantAR AR-V7civic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25184630
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AR AR-V71 | ||||||||
| Abiraterone + EnzalutamideSubstitutes | Malignant Prostate Neoplasm | Predictive | B | Supports Resistance | 3 | accepted | EID863This prospective study enrolled 31 Enzalutamide-treated (group 1) and 31 Abiraterone-treated (group 2) patients with metastatic castration-resistant prostate cancers (CRPC). AR-V7 variant was detected… (full text at CIViC) PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC | civic |
| AR SPLICE VARIANT 71 | ||||||||
| Abiraterone + EnzalutamideSubstitutes | Malignant Prostate Neoplasm | Predictive | B | Supports Resistance | 4 | rejected | EID1126In 31enzalutamide-treated and 31 abiraterone-treated patients, detectable levels of AR-V7 was associated with resistance in these patients with castration resistant prostate cancer. PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC | civic |